Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer

Award Number: R01CA286864
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/05/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2029

Group Awards By:

View Award Description

Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer - PROJECT SUMMARY Androgen receptor (AR) signaling is a major driver of prostate cancer (PCa) progression. Persistent activation of AR due to aberrant intratumoral androgen synthesis (ITAS) plays pivotal roles in resistance to therapies with the next-generation AR signaling inhibitors (ARSI) such as abiraterone. In castrated males, besides androgens produced by de novo synthesis from cholesterol, adrenal steroids dehydroepiandrosterone (DHEA) and DHEA- sulfate (DHEA-S) are the major precursors for ITAS. 3β-hydroxysteroid dehydrogenase-1 (3βHSD1), encoded by HSD3B1 gene, is a key 3βHSD enzyme that catalyzes the conversion of the adrenal-derived steroids DHEA and DHEA-S to testosterone. CHD1 is an epigenetic ‘reader’ that selectively recognizes methylated histone H3 lysine 4 such as H3K4me3, a transcription active chromatin mark. The CHD1 gene is deleted in 9-11% of both primary and advanced PCa, stressing the relevance of loss of function of CHD1 in PCa pathogenesis and progression. It has been shown that loss of CHD1 promotes AR cistrome redistribution and antiandrogen resistance in PCa cells; however, the underlying mechanism remains elusive. Our preliminary data showed that CHD1 interacts with the SIN3A corepressor protein SIN3A and that loss of CHD1 induces elevation of the total level of pan histone acetylation, increased expression of steroidogenesis genes and ITAS. We also showed that upregulation of steroids genes including HSD3B1 induced by CHD1 loss associated with increased expression of transcription factor HOXC13. Furthermore, we demonstrated that abiraterone treatment partially inhibits growth of CHD1-deficient cells and this effect is abolished by concomitant depletion of HSD3B1. Based on our novel preliminary data, we hypothesize that CHD1 functions as a transcription repressor by interacting with the SIN3A corepressor, mediating transcription repression of the HOXC13 transcription factor and downregulation androgenesis genes. However, loss of CHD1 results in transcriptional de-repression of HOXC13, which in turn induces aberrant expression of androgenesis genes, abnormal intratumoral androgen synthesis, and resistance to ARSI therapies in PCa. Aberrantly elevated 3βHSD1 and increased androgenesis represent actionable vulnerabilities for effective treatment of CHD1-deficient PCa cells. To test these hypotheses, we will determine the molecular mechanism and extent to which CHD1 interacts with SIN3A and modulates histone acetylation and transcriptional outputs in PCa (Aim 1); determine the molecular mechanism and functional importance of HOXC13 in upregulation of steroidogenesis genes and castration-resistant growth of CHD1-deficient PCa (Aim 2); and determine clinical significance and ant-cancer efficacy of pre-clinical therapeutic targeting of the deregulated CHD1-HOXC13-3βHSD1 signaling axis in PCa (Aim 3). Findings from this application will shed new light on the novel transcription repression function of CHD1, the pivotal role of the HOXC13-HSD3B1 axis in aberrant androgen synthesis and castration resistance in CHD1-deficient prostate cancer, and identification of new actionable targets for effective treatment of this subtype of prostate cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $452,180 )
2026	2026	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	000	3	4/17/2026	NON-COMPETING CONTINUATION	$452,180
														Subtotal = $452,180

Issue Date FY: 2025 ( Subtotal = $452,180 )
2025	2025	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	000	2	4/2/2025	NON-COMPETING CONTINUATION	$406,963
2025	2025	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	001	2	5/22/2025	NON-COMPETING CONTINUATION	$45,217
														Subtotal = $452,180

Issue Date FY: 2024 ( Subtotal = $452,180 )
2024	2024	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	000	1	4/5/2024	NEW	$452,180
														Subtotal = $452,180

Grand Total All Awards = $1,356,540

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer

Award Number: R01CA286864

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/05/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer